A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT ID: NCT05170204
Last Updated: 2026-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
71 participants
INTERVENTIONAL
2022-11-01
2033-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT06624059
A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy
NCT01328951
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT00556712
A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology
NCT02204345
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
NCT05171777
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A1: ALK-Positive (alectinib arm)
Participants will receive alectinib 600 mg orally twice daily until completion of treatment period (3 years), or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first
Alectinib
Participants will receive oral alectinib twice daily with food.
Cohort A1: ALK-positive (durvalumab arm)
Participants will receive 1500 mg of intravenous (IV) durvalumab every 4 weeks until completion of treatment period (1 year) or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first
Durvalumab
Participants will receive IV durvalumab every 4 weeks.
Cohort A2: ROS 1-positive (entrectinib arm)
Participants will receive entrectinib 600 mg orally once daily until completion of treatment period (3 years), or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first.
Cohort A2 has been closed to enrollment.
Entrectinib
Participants will receive oral entrectinib once daily, with or without food.
Cohort A2: ROS 1-positive (durvalumab arm)
Participants will receive 1500 mg of IV durvalumab every 4 weeks until completion of treatment period (1 year) or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first
Cohort A2 has been closed to enrollment.
Durvalumab
Participants will receive IV durvalumab every 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alectinib
Participants will receive oral alectinib twice daily with food.
Entrectinib
Participants will receive oral entrectinib once daily, with or without food.
Durvalumab
Participants will receive IV durvalumab every 4 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willingness and ability to use the electronic device(s) or application(s) for the electronic patient-reported outcome (PRO)
* Whole-body positron emission tomography/computed tomography scan (PET/CT) (from the base of skull to mid-thighs) for the purposes of staging, performed prior and within 42 days for Cohort A2 (ROS1 positive) and 50 days for Cohort A1 (ALK positive) of the first dose of cCRT or sCRT
* Histologically or cytologically documented locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology
* Prior receipt of at least two prior cycles of platinum-based chemotherapy given concurrently with radiotherapy (cCRT); or at least two prior cycles of platinum-based chemotherapy given prior to radiotherapy (sCRT)
* The RT component in the cCRT or sCRT must have been at a total dose of radiation of 60 (+/-10%) Gy (54 Gy to 66 Gy) administered by intensity-modulated radiotherapy (preferred) or three dimension (3D)-conforming technique
* No disease progression during or following platinum-based cCRT or sCRT
* Life expectancy \>/= 12 weeks
* Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen
* Tumor PD-L1 status (TC score \< 1% vs. \>/= 1% vs. unknown) as determined using the VENTANA PD-L1 IHC SP263 assay (preferred) or the Dako PD-L1 IHC 22C3 pharmDx assay
* Eastern Cooperative Oncology Group Performance Status of 0, 1, or 2
* Adequate hematologic and end-organ function
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs, as defined by the protocol
* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm, as defined by the protocol
* Documented ALK fusion positivity by an eligible result from: centralized multiplex molecular testing of tumor tissue at the Sponsor's designated central laboratory under Study BX43361 or prior tissue-based testing performed in an accredited or certified laboratory
* Documented ROS1 fusion positivity by an eligible result from: centralized multiplex molecular testing of tumor tissue at the Sponsor's designated central laboratory under Study BX43361 or available results from a Sponsor pre-approved local, appropriately validated ROS1 fusion test on tumor tissue performed in a Clinical Laboratory Improvement Amendments certified or equivalent laboratory
* Ability to swallow entrectinib intact, without chewing, crushing, or opening the capsules
Exclusion Criteria
* Any evidence of Stage IV disease, including, but not limited to, the following: pleural effusion, pericardial effusion, brain metastases, history of intracranial hemorrhage or spinal cord hemorrhage, bone metastases, distant metastases
* If a pleural effusion is present, the following criteria must be met to exclude malignant involvement (T4 disease): when pleural fluid is visible on both the CT scan and chest X-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative; participants with exudative pleural effusions are excluded regardless of cytology; participants with effusions that are minimal (i.e., not visible on chest X-ray) that are too small to safely tap are eligible
* NSCLC known to have a known or likely oncogenic-driver mutation in the EGFR gene, as identified by site local testing or Sponsor central testing
* Liver disease, characterized by any of the following: impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or other conditions of decompensated liver disease, such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices or active viral or active autoimmune, alcoholic, or other types of acute hepatitis
* Positive hepatitis B surface antigen (HBsAg) test at screening
* Participants known to be positive for hepatitis C virus (HCV) antibody (Ab) are excluded with the following exception: participants who are HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution are eligible
* HIV infection: participants are excluded if not well-controlled as defined by the protocol
* Known active tuberculosis
* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest CT scan
* Grade \>/= 2 pneumonitis from prior cCRT or sCRT
* Any Grade \> 2 unresolved toxicity from prior cCRT or sCRT
* Any gastrointestinal (GI) disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection
* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
* Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions: participants with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study; participants with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study
* History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \> 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer
* Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer
* Major surgical procedure, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
* Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment
* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during study treatment or within 5 months after the final dose of study treatment
* Treatment with investigational therapy within 28 days prior to initiation of study treatment
* Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor-alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with exceptions defined by the protocol
* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-cytotoxic T lymphocyte-associated protein 4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
* Prior allogeneic stem cell or solid organ transplantation
* Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study
* Any condition that, in the opinion of the investigator, would interfere with the evaluation of the study drug or interpretation of patient safety or study results
* Any prior Grade \>/= 3 immune-mediated adverse event or any unresolved Grade \> 1 immune-mediated adverse event while receiving any previous immunotherapy agent other than immune checkpoint blockade agents
* Presence of clinically symptomatic interstitial lung disease or interstitial pneumonitis, including radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention)
* NSCLC known to have one or more of the following ALK point mutations, as identified by site local testing or Sponsor central testing: I1171X (where X is any other amino acid), V1180L, G1202R
* Symptomatic bradycardia
* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina; participants with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction \< 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate
* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
* Prior treatment with ALK inhibitors
* History of hypersensitivity to alectinib, durvalumab, or any of their excipients
* Inability to swallow oral study drug
* Known hereditary problems of galactose intolerance, a congenital lactase deficiency, or glucose-galactose malabsorption
* Pregnancy or breastfeeding, or intending to become pregnant during the study treatment or within 90 days after the final dose of alectinib or durvalumab
* Symptomatic bradycardia
* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina; participants with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction \< 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate
* Left ventricular ejection fraction less than or equal to 50% observed during the screening for the study
* History of prolonged QTc interval (e.g., repeated demonstration of a QTc interval \> 450 ms from ECGs performed at least 24 hours apart)
* History of additional risk factors for torsade de pointes (e.g., family history of long QT syndrome)
* Familial or personal history of congenital bone disorders or bone metabolism alterations
* Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of the treatment
* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
* Prior treatment with ROS1 inhibitors
* History of hypersensitivity to entrectinib, durvalumab, and their excipients
* Grade \>/= 3 toxicities due to any prior therapy (e.g., RT) (excluding alopecia) that have not shown improvement or are not stable and are considered to interfere with current study drug
* Known hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption
* Grade \>/= 2 peripheral neuropathy
* Pregnancy or intention of becoming pregnant during study treatment, within 35 days after the final dose of entrectinib, or within 90 days after the final dose of durvalumab
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of South Alabama
Mobile, Alabama, United States
Southern California Kaiser Permanente
Los Angeles, California, United States
Rocky Mountain Cancer Centers - Lone Tree
Lone Tree, Colorado, United States
Mount Sinai Medical Center
Miami Beach, Florida, United States
University Of Michigan
Ann Arbor, Michigan, United States
Oregon Health Sciences Uni
Portland, Oregon, United States
Northwest Cancer Specialists, P.C.
Tigard, Oregon, United States
Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Thompson Cancer Survival Center
Knoxville, Tennessee, United States
Baptist Cancer Center
Memphis, Tennessee, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Mays Cancer Center, UT Health San Antonio
San Antonio, Texas, United States
Virginia Cancer Specialists (Fairfax) - USOR
Fairfax, Virginia, United States
Lifehouse
Camperdown, New South Wales, Australia
GenesisCare North Shore
St Leonards, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
One Clinical Research
Nedlands, Western Australia, Australia
GHdC Site Les Viviers
Charleroi, , Belgium
UZ Gent
Ghent, , Belgium
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
Hospital Sao Rafael - HSR
Salvador, Estado de Bahia, Brazil
Instituto do Cancer Brasil
Três Lagoas, Mato Grosso do Sul, Brazil
Oncocentro Belo Horizonte
Belo Horizonte, Minas Gerais, Brazil
COT - Centro Oncologico do Triangulo
Uberlândia, Minas Gerais, Brazil
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
Clínica de Oncologia Reichow
Blumenau, Santa Catarina, Brazil
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil
Oncoclinicas Rio de Janeiro S.A.
Rio de Janeiro, , Brazil
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
K2 Oncology
Providencia, , Chile
Centro de Estudios Clínicos SAGA
Santiago, , Chile
OrlandiOncología
Santiago, , Chile
RedSalud Vitacura
Santiago, , Chile
James Lind Centro de Investigación Del Cáncer
Temuco, , Chile
Beijing Cancer Hospital
Beijing, , China
Hunan Cancer Hospital
Changsha, , China
Hunan Cancer Hospital
Changsha, , China
Xinqiao Hospital of Third Military Medical University
Chongqing, , China
Shandong Cancer Hospital
Jinan, , China
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
Nanjing, , China
The affiliated hospital of Qingdao university
Qingdao, , China
Shanghai Pulmonary Hospital
Shanghai, , China
Tianjin Medical University Cancer Institute & Hospital
Tianjing, , China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, , China
Shanxi Cancer Hospital
Xi'an, , China
Clinica De La Costa
Barranquilla, , Colombia
Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo
Bogota, D.C., , Colombia
Hospital Universitario San Ignacio
Bogotá, , Colombia
Instituto Cancerología Medellin
Medellín, , Colombia
Clinica CIMCA
San José, , Costa Rica
ICIMED Instituto de Investigación en Ciencias Médicas
San José, , Costa Rica
CHU Angers,Service de Pneumologie
Angers, , France
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, , France
Hôpital Ambroise Paré - Boulogne-Billancourt
Boulogne-Billancourt, , France
Centre Francois Baclesse
Caen, , France
Centre Leon Berard
Lyon, , France
Hopital Nord
Marseille, , France
Hôpitaux D'Instruction Des Armees Begin
Saint-Mandé, , France
CHU Strasbourg - Nouvel Hopital Civil
Strasbourg, , France
Hia Sainte Anne
Toulon, , France
CHU de Toulouse - Hôpital Larrey
Toulouse, , France
Helios Klinikum Emil von Behring GmbH
Berlin, , Germany
Klinikum Chemnitz gGmbH
Chemnitz, , Germany
Klinikum Esslingen
Esslingen am Neckar, , Germany
Thoraxklinik Heidelberg gGmbH
Heidelberg, , Germany
LMU Klinikum der Universität München, Medizinische Klinik und Poliklinik V, Campus Innenstadt
München, , Germany
Universitätsklinikum Regensburg
Regensburg, , Germany
Universitätsklinikum Würzburg
Würzburg, , Germany
Queen Mary Hospital
Hong Kong, , Hong Kong
Medanta-The Medicity
Gurgaon, Haryana, India
Tata Memorial Hospital
Mumbai, Maharashtra, India
Rajiv Gandhi Cancer Inst.&Research Center
New Delhi, National Capital Territory of Delhi, India
Apollo Gleneagles Hospital
Kolkata, West Bengal, India
Rambam Medical Center
Haifa, , Israel
Rabin Medical Center-Beilinson Campus
Petah Tikva, , Israel
IRCCS Giovanni Paolo II Istituto Oncologico
Bari, Apulia, Italy
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola
Meldola, Emilia-Romagna, Italy
IRCCS Istituto Regina Elena (IFO)
Rome, Lazio, Italy
Azienda Ospedaliera San Camillo Forlanini
Rome, Lazio, Italy
IRCCS A.O.U San MArtino - IST
Genoa, Liguria, Italy
Asst Degli Spedali Civili Di Brescia
Brescia, Lombardy, Italy
Irccs Istituto Europeo di Oncologia (IEO)
Milan, Lombardy, Italy
Asst Grande Ospedale Metropolitano Niguarda
Milan, Lombardy, Italy
A.O. Universitaria S. Luigi Gonzaga
Orbassano, Piedmont, Italy
Azienda Ospedaliero-Universitaria Careggi
Florence, Tuscany, Italy
IRCCS Istituto Oncologico Veneto (IOV)
Padua, Veneto, Italy
Ospedale P. Pederzoli Casa di cura Privata
Peschiera Del Garda (VR), Veneto, Italy
Aichi Cancer Center Hospital
Aichi, , Japan
Hirosaki University Hospital
Aomori, , Japan
National Cancer Center East
Chiba, , Japan
Shikoku Cancer Center
Ehime, , Japan
NHO Kyushu Cancer Center
Fukuoka, , Japan
Kurume University Hospital
Fukuoka, , Japan
Kobe City Medical Center General Hospital
Hyōgo, , Japan
National Hospital Organization Himeji Medical Center
Hyōgo, , Japan
Kagoshima University Hospital
Kagoshima, , Japan
Kanagawa Cancer Center
Kanagawa, , Japan
Kumamoto University Hospital
Kumamoto, , Japan
Sendai Kousei Hospital
Miyagi, , Japan
Nara Medical University Hospital
Nara, , Japan
Niigata Cancer Center Hospital
Niigata, , Japan
Okayama University Hospital
Okayama, , Japan
Kurashiki Central Hospital
Okayama, , Japan
Osaka City General Hospital
Osaka, , Japan
Osaka International Cancer Institute
Osaka, , Japan
NHO Kinki Chuo Chest Medical Center
Osaka, , Japan
Kindai University Hospital
Ōsaka-sayama, , Japan
Shizuoka Cancer Center
Shizuoka, , Japan
Juntendo University Hospital
Tokyo, , Japan
Komagome Hospital
Tokyo, , Japan
The Cancer Institute Hospital of JFCR
Tokyo, , Japan
Tottori University Hospital
Tottori, , Japan
National Hospital Organization Yamaguchi - Ube Medical Center
Yamaguchi, , Japan
Hospital Civil de Guadalajara Fray Antonio Alcalde
Guadalajara, Jalisco, Mexico
Clinstile S.A de C.V.
Mexico City, Mexico CITY (federal District), Mexico
Centro de Investigación Oncologica Galerias
Aguascalientes, , Mexico
ARKE Estudios Clínicos S.A. de C.V.
Mexico City, , Mexico
Maastricht University Medical Center
Maastricht, , Netherlands
Auckland City Hospital, Cancer and Blood Research
Auckland, , New Zealand
Oslo university hospital Radiumhospitalet
Oslo, , Norway
Instytut Genetyki i Immunologii GENIM
Lublin, , Poland
Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
Olsztyn, , Poland
Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
Poznan, , Poland
Dolno?l?skie Centrum Chorób P?uc we Wroc?awiu
Wroc?aw, , Poland
University Clinical Centre of Serbia
Belgrade, , Serbia
Hospital Medical Center Bezanijska kosa
Belgrade, , Serbia
Institute for Pulmonary Diseases of Vojvodina
Kamenitz, , Serbia
Univ Clinical Center Kragujevac
Kragujevac, , Serbia
National Cancer Centre
Singapore, , Singapore
Tan Tock Seng Hospital
Singapore, , Singapore
Chungbuk National University Hospital
Cheongju-si, , South Korea
Kyungpook National University Chilgok Hospital
Daegu, , South Korea
Pusan National University Yangsan Hospital
Gyeongsangnam-do, , South Korea
Chonnam National University Hwasun Hospital
Jeollanam-do, , South Korea
Seoul National University Bundang Hospital
Seongnam-si, , South Korea
Kangbuk Samsung Hospital
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, LA Coruna, Spain
Complejo Hospitalario Universitario Insular?Materno Infantil
Las Palmas de Gran Canaria, LAS Palmas, Spain
Hospital General Univ. de Alicante
Alicante, , Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Ramon y Cajal
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Hospital Regional Universitario Carlos Haya
Málaga, , Spain
Hospital Universitario Virgen del Rocio
Seville, , Spain
Hospital Clínico Universitario de Valencia
Valencia, , Spain
Sahlgrenska University Hospital
Gothenburg, , Sweden
Karolinska Universitetssjukhuset, Solna
Stockholm, , Sweden
Taipei Medical University ?Shuang Ho Hospital
New Taipei City, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
National Cheng Kung Univ Hosp
Tainan, , Taiwan
National Taiwan Uni Hospital
Taipei, , Taiwan
Taipei Medical University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Taipei Municipal Wan Fang Hospital
Taipei, , Taiwan
Chang Gung Memorial Hospital - Linkou
Taoyuan District, , Taiwan
Rajavithi Hospital
Bangkok, , Thailand
Faculty of Med. Siriraj Hosp.
Bangkok, , Thailand
Oncology Unit, Faculty of Medicine, Vajira Hospital
Dusit, , Thailand
Songklanagarind Hospital
Songkhla, , Thailand
Ataturk Sanatoryum Egitim Ve Arastirma Hastanesi
Ankara, , Turkey (Türkiye)
Gazi Uni Medical Faculty Hospital
Ankara, , Turkey (Türkiye)
Liv Hospital Ankara
Ankara, , Turkey (Türkiye)
Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji
Bakirkoy / Istanbul, , Turkey (Türkiye)
Dicle University Faculty of Medicine
Diyarbakır, , Turkey (Türkiye)
Ataturk University Medical Faculty Yakutiye Research Hospital Medical Oncology Department
Erzurum, , Turkey (Türkiye)
Medipol University Medical Faculty
Istanbul, , Turkey (Türkiye)
Marmara Uni Faculty of Medicine
Istanbul, , Turkey (Türkiye)
Medikal Park Samsun
Samsun, , Turkey (Türkiye)
Medical Park Seyhan Hospital
Seyhan, , Turkey (Türkiye)
Birmingham Heartlands Hospital
Birmingham, , United Kingdom
North Middlesex Hospital
Harlow, , United Kingdom
Barts & London School of Med
London, , United Kingdom
Royal Marsden Hospital
London, , United Kingdom
Christie Hospital Nhs Trust
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Reference Study ID Number: BO42777 https://forpatients.roche.com/
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-503920-14-00
Identifier Type: CTIS
Identifier Source: secondary_id
BO42777
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.